


ATC codes: [L02AE02](#)

Indication	Malignant neoplasms of prostate ICD11 code: 2D32.Z
INN	Leuprorelin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IM: 7.5 mg in prefilled syringe ; 22.5 mg in prefilled syringe
EML status history	First added in 2015 (TRS 994)
Sex	Male
Age	Adolescents and adults
Therapeutic equivalence	Medicines within the same pharmacological class can be used
Patent information	Patents have expired in most jurisdictions Read more about patents . 

Tags

Cancer

Wikipedia

[Leuprorelin](#) 

DrugBank

[Leuprorelin \(Leuprolide\)](#) 

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, leuprorelin (with a square box) was added to the complementary list of the EML for use in the treatment of metastatic prostate cancer. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic prostate cancer is attached.

[Expert Committee report](#) 

